Moderna Inc told the media on Tuesday that it is planning to price its vaccine at $50 to $60 per course, at least $11, which will be more than Pfizer Inc and BioNTech. The price proposed by Moderna is for a two- dose course sold to government, whereas Pfizer Inc has priced it as $11 for two doses. Industry analysts state that Pfizer and BioNTech’s $2 billion deal will cover 50 million patients.
Moderna's pricing is most likely to be applicable for United States and other High- income countries as per the report.
A Moderna spokesperson told media that the company is in talks with government about the supply of vaccine, but has not provided any details on pricing. Reuters reported that according to sources, the price of the vaccine is yet to be determined.
Pfizer, Moderna and Merck & Co have said they plan to sell their vaccines at a profit, while some drugmakers, including Johnson & Johnson have announced that their vaccines will not be priced on the basis of profit.
OTHER NEWS SHOTS
